© BusinessWire
29.03.2025
TEM
LISTED
NASDAQ
Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the American College of Cardiology (ACC) Annual Meeting, which convenes from March 29-31 in Chicago, Illinois. This is the first year that Tempus is presen...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
ATNM
LISTED
XASE
Rosen Law Firm Urges Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022, and August 2, 2024. Actinium describes itself as a “late-stage biopharmaceutical company that develops targeted radiotherapies.”...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
ATNM
LISTED
XASE
Securities Fraud Investigation Into Actinium Pharmaceuticals, Inc. (ATNM) Announced – Investors Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
News Preview
The Law Offices of Frank R. Cruz announces an investigation of Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON ACTINIUM PHARMACEUTICALS, INC. (ATNM), CLICK HERE TO INQUIRE ABOU...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
28.03.2025
BLUE
LISTED
NASDAQ
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
News Preview
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrmid Ltd (“Ayrmid”) to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone....
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
28.03.2025
TRAW
LISTED
NASDAQ
Traws Pharma Announces Management Updates
News Preview
NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Of...
Themefolio
Profiler
Peergroup
© BusinessWire
28.03.2025
ATNM
LISTED
XASE
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE American: ATNM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchan...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.03.2025
DBV
LISTED
EURONEXT
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved
News Preview
Châtillon, France, March 27, 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
27.03.2025
ATNM
LISTED
XASE
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Actinium Pharmaceuticals, Inc. (NYSE American: ATNM)
News Preview
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Southern District of New York against Actinium Pharmaceuticals, Inc. (“Actinium” or the “Company”) (NYSE American: ATNM), and certain of its form...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
IMMNOV
LISTED
STO
Immunovia announces determined exercise price for warrants series TO 3
News Preview
LUND, Sweden, March 27, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 3 (the "warrants") has been determined to SEK 0.24. The exercise period for the warrants commences on 1 April 2025 and runs up to and including 15 April 2025. The last day for trading in t...
Themefolio
Profiler
Peergroup
© ActuNews
27.03.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – March 27, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received transparency notifications as follows:
Oxurion received a transparency notification on March 27, 2025, from Atlas...
Themefolio
Profiler
Peergroup
© ActuNews
27.03.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 27 maart 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende transparantiekennisgevingen heeft ontvangen:
Oxurion ontving een transpara...
Themefolio
Profiler
Peergroup
© ActuNews
27.03.2025
OXUR
LISTED
EURONEXT
Oxurion Receives Amended Transparency Notification from Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIUM – March 27, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received an amended transparency notification as follows:
Oxurion received a transparency notification on March 27, 2025,...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ActuNews
27.03.2025
OXUR
LISTED
EURONEXT
Oxurion ontvangt aangepaste transparantiekennisgeving van Atlas Special Opportunities II LLC
News Preview
Leuven, BELGIË – 27 maart 2025 – 18u00 CET Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, België, heeft vandaag aangekondigd dat het, in overeenstemming met de Belgische transparantiewetgeving1, de volgende aangepaste transparantiekennisgeving heeft ontvangen:
Oxurion ontving een...
Themefolio
Profiler
Peergroup
© Globe Newswire
27.03.2025
ZEAL
LISTED
CPH
Resolutions from Zealand Pharma's Annual General Meeting 2025
News Preview
Company announcement – No. 7 / 2025...
Themefolio
Profiler
Peergroup
© EQS Newswire
27.03.2025
SRT3
LISTED
XETR
Sartorius AG – Beschlüsse der Hauptversammlung
News Preview
Göttingen, 27. März 2025
Sartorius AG – Beschlüsse der Hauptversammlung
Der Life-Science-Konzern Sartorius hat heute virtuell seine Hauptversammlung abgehalten. Die Aktionärinnen und Aktionäre stimmten allen Vorschlägen von Aufsichtsrat und Vorstand mit großer Mehrheit zu, einschließlich des Dividendenvorschlags in Höhe von 0,74 Euro je Vorzugsak......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.03.2025
SRT3
LISTED
XETR
Sartorius AG - Resolutions of the Annual General Meeting
News Preview
Göttingen, Germany | March 27, 2025
Sartorius AG - Resolutions of the Annual General Meeting
The life science group Sartorius held its virtual Annual General Meeting today. The shareholders approved all proposals of the Supervisory Board and the Executive Board by a large majority, including the dividend proposal of 0.74 euros per preference share......
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
GETI B
LISTED
STO
Getinge publishes Annual Report for 2024
News Preview
GOTHENBURG, Sweden, March 27, 2025 /PRNewswire/ -- Today, Getinge publishes its Annual Report, including Sustainability Report, for 2024. The report summarizes a year characterized by strong growth, increased customer satisfaction, and successful product launches. The global medtech company has reached new sales records, strengthened its acquisit...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
GETI B
LISTED
STO
Getinge publishes Annual Report for 2024
News Preview
GOTHENBURG, Sweden, March 27, 2025 /PRNewswire/ -- Today, Getinge publishes its Annual Report, including Sustainability Report, for 2024. The report summarizes a year characterized by strong growth, increased customer satisfaction, and successful product launches. The global medtech company has reached new sales records, strengthened its acquisit...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
News Preview
- 99.8% tumor growth inhibition achieved with a single dose of ATNM-400 in preclinical prostate cancer models
- ATNM-400 accumulated in tumors for up to 144 hours and showed minimal uptake in healthy tissues in prostate cancer xenograft model
- Initial ATNM-400 preclinical data to be presented at AACR including results in Pluvicto resistant pro...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives
News Preview
- ATNM-400 is a novel, non-PSMA targeting, first-in-class Actinium-225 radiotherapy for prostate cancer with initial preclinical results to be presented at the AACR Annual Meeting
- Actinium is establishing radiopharmaceutical manufacturing infrastructure in 2025 to support expanding clinical trials and to leverage its proprietary Actinium-225 cy...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
VITR
LISTED
STO
Vitrolife Group Annual and Sustainability Report 2024
News Preview
GOTHENBURG, Sweden, March 27, 2025 /PRNewswire/ -- Vitrolife Group has today published its Annual and Sustainability Report for 2024.
The Annual and Sustainability Report is now available digitally in English and Swedish at www.vitrolifegroup.com. The Annual Report in accordance with European Single Electronic Format (ESEF) is available in Swedi...
Themefolio
Profiler
Peergroup
© PR Newswire
27.03.2025
AFX
LISTED
XETR
ILM-Blue from DORC Receives NMPA Approval in China; Expanding Global Reach
News Preview
JENA, Germany, March 27, 2025 /CNW/ -- ZEISS Medical Technology announced today that the ILM staining dye ILM-Blue® from DORC (Dutch Ophthalmic Research Center (International) B.V.) has received National Medical Products Administration (NMPA) approval in China, marking a significant milestone in the product's global journey....
Themefolio
Profiler
Peergroup
© EQS Newswire
27.03.2025
EUZ
LISTED
XETR
Rekordjahr 2024 mit neuen Höchstmarken
News Preview
Berlin, den 27. März 2025. Die Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) erreichte auf Basis des vorläufigen Jahresabschlusses* im Geschäftsjahr 2024 mit einem Umsatz von 295,8 Mio. € eine neue Rekordmarke. Im Vergleich zum Vorjahr stieg der Umsatz um knapp 50 Mio. € (+20%). Das EBIT vor Sondereinflüssen aus fortgeführten Geschäftsbereich......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.03.2025
EUZ
LISTED
XETR
Record year 2024 with new all-time highs
News Preview
Berlin, 27 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) achieved a new record in the 2024 financial year with sales of € 295.8 million based on the preliminary annual financial statements*. Compared to the previous year, sales increased by almost € 50 million (+20%). EBIT before special items from continuing operations (adjusted ......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.03.2025
FYB
LISTED
XETR
Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
News Preview
Press Release // March 27, 2025
Formycon reports on a successful financial year 2024 with strong operational progress and continuous strengthening of its market position
Group revenue exceeds forecast with €69.7 million (guidance: €55.0 million to €65.0 million)
Group EBITDA at €-13.7 million also better than expected (guidance: €-25.0 mil......
Themefolio
Profiler
Peergroup
© EQS Newswire
27.03.2025
FYB
LISTED
XETR
Formycon berichtet über erfolgreiches Geschäftsjahr 2024 mit starken operativen Fortschritten und kontinuierlichem Ausbau der Marktposition
News Preview
Pressemitteilung // 27. März 2025
Formycon berichtet über erfolgreiches Geschäftsjahr 2024 mit starken operativen Fortschritten und kontinuierlichem Ausbau der Marktposition
Konzernumsatz übertrifft mit 69,7 Mio. € prognostizierte Erwartungen (55,0 Mio. € bis 65,0 Mio. €)
Konzern EBITDA mit -13,7 Mio. € ebenfalls besser als Prognose (-......
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
News Preview
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update...
Themefolio
Profiler
Peergroup
© Globe Newswire
26.03.2025
NSIS B
LISTED
CPH
Trading by management and close relations of management
News Preview
Please read the full announcement in PDF...
Themefolio
Profiler
Peergroup
© PR Newswire
26.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today
News Preview
- Company to highlight recent significant progress made with its Actimab-A and Iomab-ACT clinical programs, leading-edge R&D and radiopharmaceutical manufacturing infrastructure
- Revitalized clinical programs focused on 3 separate multi-billion-dollar market opportunities in myeloid malignancies, solid tumors and cell & gene therapy cond...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
TEM
LISTED
NASDAQ
Tempus to Present at the 24th Annual Needham Virtual Healthcare Conference
News Preview
Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the 24th Annual Needham Virtual Healthcare Conference on April 7-10, 2025.
Tempus’ Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Wednesday, April 9. A...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
LIVN
LISTED
NASDAQ
LivaNova to Announce First-Quarter 2025 Results
News Preview
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its first-quarter 2025 results prior to the call.
The audiocast will be accessible at www.livanova.com/event...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
ZLAB
LISTED
NASDAQ
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
News Preview
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company’s internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunothe...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.03.2025
GMAB
LISTED
CPH
Genmab Announces Initiation of Share Buy-Back Program
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© PR Newswire
25.03.2025
VITR
LISTED
STO
Notice to attend the Annual General Meeting of Vitrolife AB (publ)
News Preview
GOTHENBURG, Sweden, March 25, 2025 /PRNewswire/ -- The shareholders of Vitrolife AB (publ) are hereby invited to attend the Annual General Meeting of shareholders on 29 April 2025 at 4.00 pm at the Elite Park Avenue Hotel, Kungsportsavenyn 36-38 in Gothenburg, Sweden. The entrance opens at 3.30 pm.
Shareholders who wish to attend the Annual Gen...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.03.2025
ZEAL
LISTED
CPH
Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
News Preview
Company announcement – No. 6 / 2025...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.03.2025
DIM
LISTED
EURONEXT
Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.
News Preview
Sartorius Stedim Biotech SA
/ Key word(s): AGM/EGM
Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A. 25-March-2025 / 15:35 CET/CEST
Aubagne, France | March 25, 2025
Resolutions of the Combined Annual Shareholders’ Meeting of Sartorius Stedim Biotech S.A.At today’s combined Annual Shareh......
Themefolio
Profiler
Peergroup
© PR Newswire
25.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program
News Preview
- Actinium will present 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning
- Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin to highlight Actimab-A clinical results, mutation agnostic mechanism and b...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.03.2025
POAI
LISTED
NASDAQ
Predictive Oncology Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
News Preview
Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.03.2025
EUZ
LISTED
XETR
Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities
News Preview
Berlin, DE & New York, USA, 25 March 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) and Actinium Pharmaceuticals, Inc. announced that they have entered into an agreement for the supply of Actinium-225 (Ac-225). With this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler’s high-purity Actinium-225 to further......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.03.2025
EUZ
LISTED
XETR
Eckert & Ziegler beliefert Actinium Pharmaceuticals mit Ac-225 für umfangreiches Entwicklungsprogramm
News Preview
Berlin, DE & New York, USA, 25. März 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) und Actinium Pharmaceuticals, Inc. gaben bekannt, dass sie eine Vereinbarung über die Lieferung von Actinium-225 (Ac-225) geschlossen haben. Mit dieser Vereinbarung erhält Actinium Pharmaceuticals Zugang zu Eckert & Zieglers hochreinem Actinium-22......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.03.2025
ILM1
LISTED
XETR
Medios erwartet nach Rekordjahr 2024 weiteres Wachstum bei Umsatz und Ergebnis
News Preview
Pressemitteilung
Medios erwartet nach Rekordjahr 2024 weiteres Wachstum bei Umsatz und Ergebnis
Konzernumsatz steigt auf 1,9 Mrd. € (+5,5 %)
EBITDA pre1 mit überproportionalem Wachstum von 30,5 % und deutlich besserer EBITDA-pre1-Marge von 4,2 % (Vj. 3,4 %)
Starker operativer Cashflow
Ausblick 2025: Umsatzanstieg auf rund 2,0 Mrd. €; EBITDA-p......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.03.2025
ILM1
LISTED
XETR
Medios expects further growth in revenue and earnings after record year 2024
News Preview
Press release
Medios expects further growth in revenue and earnings after record year 2024
Consolidated revenue increases to €1.9 billion (+5.5%)
EBITDA pre1 with disproportionate growth of 30.5% and significantly improved EBITDA pre1 margin of 4.2% (previous year: 3.4%)
Strong operating cash flow
Outlook for 2025: revenue growth to around €2.......
Themefolio
Profiler
Peergroup
© PR Newswire
24.03.2025
ATNM
LISTED
XASE
Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities
News Preview
NEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will ha...
Themefolio
Profiler
Peergroup
© BusinessWire
24.03.2025
DFTX
LISTED
NASDAQ
MindMed Announces New Employee Inducement Grants
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the issuance of inducement grants to four newly hired non-executive employees consisting of options to purchase an aggregate of 88,950 common...
Themefolio
Profiler
Peergroup
© ActuNews
24.03.2025
OXUR
LISTED
EURONEXT
OXURION : Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op Atlas Conversie-Notificatie
News Preview
Atlas Special Opportunities, LLC heeft 6 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 150.000. Deze conversie vormt deel van Atlas Special Opportunities, LLC's EUR 20 miljoen kapitaaltoezegging1 die aan Oxurion zal toelaten om te focussen op het ontwikkelen van innovatieve geneesmiddelen om he...
Themefolio
Profiler
Peergroup
© ActuNews
24.03.2025
OXUR
LISTED
EURONEXT
OXURION : Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
News Preview
Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment[1] that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential ma...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.03.2025
IBAB
LISTED
EURONEXT
IBA – Share buyback
News Preview
Louvain-la-Neuve, Belgium, March 24th, 2025 - Ion Beam Applications SA (IBA) announces today the launch of a share buyback program, effective as of March 25th, 2025, in application of article 7:215 of the Belgian Companies and Associations Code....
Themefolio
Profiler
Peergroup
© PR Newswire
24.03.2025
IMMNOV
LISTED
STO
Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test
News Preview
LUND, Sweden, March 24, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company's position as it prepares to launch the pancreatic cancer blood test commercially...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.03.2025
NSIS B
LISTED
CPH
Transactions under Novonesis’ share buyback program
News Preview
Please read the announcement in PDF...
Themefolio
Profiler
Peergroup
© BusinessWire
24.03.2025
ICLR
LISTED
NASDAQ
Kessler Topaz Meltzer & Check, LLP Reminds ICLR Shareholders of Deadline in Securities Fraud Class Action Lawsuit Filed Against ICON Public Limited Company (ICLR)
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against ICON Public Limited Company (“ICON”) (NASDAQ: ICLR) on behalf of all purchasers of ICON ordinary shares between July 27, 2023 and October 23, 2024, inclusive (the “Class Period”). The lead plaintiff...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.03.2025
ANAB
LISTED
NASDAQ
Anaptys Announces Stock Repurchase Plan
News Preview
SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $75,000,000 of the Company’s outstanding com...
Themefolio
Profiler
Peergroup
© Globe Newswire
24.03.2025
CELC
LISTED
NASDAQ
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call
News Preview
MINNEAPOLIS, March 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2024 after the market closes on Monday, March 31, 2025. Management will host a...
Themefolio
Profiler
Peergroup
© EQS Newswire
24.03.2025
FYB
LISTED
XETR
Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
News Preview
Press Release // March 24, 2025
Formycon invites to conference call on the results of the financial year 2024 and announces participation in international investor conferences in the 2nd quarter of 2025
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today announced details of the conference call for the release of the fisca......
Themefolio
Profiler
Peergroup
© EQS Newswire
24.03.2025
FYB
LISTED
XETR
Formycon lädt zur Telefonkonferenz zu den Ergebnissen des Geschäftsjahres 2024 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 2. Quartal 2025 bekannt
News Preview
Pressemitteilung // 24. März 2025
Formycon lädt zur Telefonkonferenz zu den Ergebnissen des Geschäftsjahres 2024 ein und gibt Teilnahme an internationalen Investorenkonferenzen im 2. Quartal 2025 bekannt
Planegg-Martinsried – Die Formycon AG (FWB: FYB, Prime Standard, „Formycon“) hat heute Details zur Telefonkonferenz bezüglich der Veröffentlich......
Themefolio
Profiler
Peergroup
© Globe Newswire
22.03.2025
GMAB
LISTED
CPH
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2025
HNSA
LISTED
STO
Hansa Biopharma publishes 2024 Annual and Sustainability Reports
News Preview
LUND, Sweden, March 21, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ Stockholm: HNSA), today published its Annual and Sustainability Reports for 2024.
Peter Nicklin, Chair of the Board, Hansa Biopharma, said: "Hansa delivered several important milestones in 2024 and remains on track to advance innovative science and...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2025
HNSA
LISTED
STO
Hansa Biopharma publishes 2024 Annual and Sustainability Reports
News Preview
LUND, Sweden, March 21, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (NASDAQ Stockholm: HNSA), today published its Annual and Sustainability Reports for 2024.
Peter Nicklin, Chair of the Board, Hansa Biopharma, said: "Hansa delivered several important milestones in 2024 and remains on track to advance innovative science and...
Themefolio
Profiler
Peergroup
© PR Newswire
21.03.2025
IMMNOV
LISTED
STO
Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study
News Preview
LUND, Sweden, March 21, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, published positive results from the VERIFI clinical validation of its next-generation test for pancreatic cancer on March 19, 2025. As a follow up, Immunovia will host a webcast on Monday, March 24 at 3 pm CET.
Jeff Borch...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.03.2025
ORNBV
LISTED
HEL
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS21 March 2025 at 15.00 EET ...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.03.2025
OXB
LISTED
LSE
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category
News Preview
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
